RWDD2A

Across TCGA pan-cancer cohorts, RWDD2A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RWDD2A data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RWDD2A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RWDD2A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

GBM, PDAC, and LSCC are the cancer types where RWDD2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.798	0.962	.003	6	view →
PDAC	OS	Median	II,III,IV	1.000	0.593	.049	1	view →
LSCC	OS	Quartile	All	0.660	0.937	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RWDD2A–GBM (OS)

Open the GBM breakdown →